Verastem, Inc. Files 8-K Report

TL;DR

Verastem filed an 8-K, standard reporting, check exhibits for news.

AI Summary

On July 23, 2024, Verastem, Inc. filed an 8-K report detailing an "Other Event" and "Financial Statements and Exhibits." The filing does not disclose specific financial figures or significant corporate actions beyond the standard reporting requirements.

Why It Matters

This filing indicates Verastem, Inc. is meeting its regulatory reporting obligations. Investors should review the exhibits for any material updates not explicitly detailed in the summary.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain information that suggests an immediate change in risk for the company.

Key Players & Entities

• Verastem, Inc. (company) — Registrant
• July 23, 2024 (date) — Date of earliest event reported
• 001-35403 (other) — Commission File Number
• 27-3269467 (other) — IRS Employer Identification No.
• Needham, MA (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value per share VSTM The Nasdaq
• $3 — ombined offering price to the public of $3.00, less the underwriting discounts and
• $2 — ombined offering price to the public of $2.999, which is equal to the combined off
• $0.001 — Stock and accompanying Warrant less the $0.001 exercise price of each Pre-Funded Warra
• $51.1 m — eeds from the Offering of approximately $51.1 million, after deducting underwriting dis
• $3.50 — derlying share of Common Stock equal to $3.50. Each Warrant is exercisable for the nu

Filing Documents

• tm2413643d5_8k.htm (8-K) — 33KB
• tm2413643d5_ex1-1.htm (EX-1.1) — 253KB
• tm2413643d5_ex4-1.htm (EX-4.1) — 80KB
• tm2413643d5_ex4-2.htm (EX-4.2) — 75KB
• tm2413643d5_ex5-1.htm (EX-5.1) — 11KB
• tm2413643d5_ex99-1.htm (EX-99.1) — 6KB
• tm2413643d5_ex4-1img002.jpg (GRAPHIC) — 10KB
• tm2413643d5_ex4-2img001.jpg (GRAPHIC) — 10KB
• tm2413643d5_ex5-1img001.jpg (GRAPHIC) — 3KB
• tm2413643d5_ex5-1img002.jpg (GRAPHIC) — 4KB
• 0001104659-24-082526.txt ( ) — 770KB
• vstm-20240723.xsd (EX-101.SCH) — 3KB
• vstm-20240723_lab.xml (EX-101.LAB) — 33KB
• vstm-20240723_pre.xml (EX-101.PRE) — 22KB
• tm2413643d5_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On July 23, 2024, Verastem, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named in Schedule I thereto (the "Underwriters"), relating to the underwritten offering, issuance and sale by the Company of: (i) 13,333,334 shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock") and accompanying warrants (the "Warrants") to purchase up to 13,333,334 shares of Common Stock; and (ii) to certain investors, pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 5,000,000 shares of Common Stock and accompanying Warrants to purchase 5,000,000 shares of Common Stock (collectively, the "Offering"). All of the Firm Shares, the Pre-Funded Warrants and the Warrants will be sold by the Company. Each share of Common Stock is being offered and sold together with an accompanying Warrant at a combined offering price to the public of $3.00, less the underwriting discounts and commissions, and each Pre-Funded Warrant is being offered and sold together with an accompanying Common Stock Warrant at a combined offering price to the public of $2.999, which is equal to the combined offering price per share of Common Stock and accompanying Warrant less the $0.001 exercise price of each Pre-Funded Warrant, less the underwriting discounts and commissions. The Company expects to receive net proceeds from the Offering of approximately $51.1 million, after deducting underwriting discounts and commissions and estimated offering expenses. The Offering was made pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-275408), which was declared effective on November 20, 2023. The closing of the Offering is expected to take place on or about July 25, 2024, subject to the satisfaction of customary closing conditions. Each Pre-Funded Warrant will have

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: July 25, 2024 By: /s/ Daniel W. Paterson Daniel W. Paterson President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR